Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine

Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Marianne Pavel, John D. Hainsworth, Éric Baudin et al. · The Lancet · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +16

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system

Guido Rindi, Günter Klöppel, Anne Couvelard et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2007 · 954 citations · Full text

Medicine, Oncology, Surgery +17

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Éric Baudin, Anne Couvelard, Eric P. Krenning et al. · Neuroendocrinology · 2012 · 870 citations

Medicine, Oncology, Surgery +17

Radiolabeled Somatostatin Analog [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Dik J. Kwekkeboom, Jaap J.M. Teunissen, Willem H. Bakker et al. · Journal of Clinical Oncology · 2005 · 659 citations · Full text

Medicine, Oncology, Pharmacology +15